BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 19098907)

  • 1. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
    Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
    Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
    Real PJ; Ferrando AA
    Leukemia; 2009 Aug; 23(8):1374-7. PubMed ID: 19357700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of NOTCH1 signaling in T-ALL.
    Ferrando AA
    Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances on NOTCH signaling in T-ALL.
    Tzoneva G; Ferrando AA
    Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.
    Zhou Y; Guan L; Li W; Jia R; Jia L; Zhang Y; Wen X; Meng S; Ma D; Zhang N; Ji M; Liu Y; Ji C
    Cancer Lett; 2022 May; 533():215608. PubMed ID: 35240234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
    Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
    Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
    Palomero T; Ferrando A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
    Liu S; Breit S; Danckwardt S; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2009 Jul; 88(7):613-21. PubMed ID: 19057901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-secretase inhibitors: Notch so bad.
    Grosveld GC
    Nat Med; 2009 Jan; 15(1):20-1. PubMed ID: 19129776
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
    Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
    Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
    Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
    Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.